Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer

Lauren Folgosa Cooley, Kimberly A. McLaughlin, Joshua J. Meeks*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.

Original languageEnglish (US)
Pages (from-to)35-46
Number of pages12
JournalUrologic Clinics of North America
Volume47
Issue number1
DOIs
StatePublished - Feb 2020

Keywords

  • BCG
  • Bladder cancer
  • Genomics
  • Immunotherapy
  • Mutation

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer'. Together they form a unique fingerprint.

  • Cite this